Shanghai Haoyuan Chemexpre (688131.SS) traded flat 0 % during a 24 hours period ending at 06:30 PM Central Europe on Tuesday 27th. One Shanghai Haoyuan Chemexpre stock can currently be bought for about CNY 77.81 on popular exchanges. Current supply of Shanghai Haoyuan Chemexpre stocks is 213.2 mn. Shanghai Haoyuan Chemexpre has a current market capitalization of CNY 17.1 bn and approximately CNY 289.5 mn worth of Shanghai Haoyuan Chemexpre was traded on exchanges in the last 24 hours. Since last month end, Shanghai Haoyuan Chemexpre has traded -17.62 % down. Simple moving average of last 200 days is at CNY 87.34. The highest price of past 52 weeks was recorded at CNY 111.3 on 09/24/2026. 52 weeks low was at CNY 59.68 on 03/13/2026.

Summary of the latest news for Shanghai Haoyuan Chemexpre

On 27 October, Shanghai Haoyuan Chemexpert’s share price experienced a moderate decline after the company’s latest quarterly report was released. The report detailed the performance of the firm’s products, noting a slight drop in revenue compared with the previous quarter. Analysts highlighted the company’s continued focus on its core chemical and pharmaceutical research portfolio, while noting that the firm’s operating margins remained stable. In the days following the release, market participants observed a modest rise in trading volume, suggesting ongoing investor interest. No material changes were reported regarding the company’s strategic direction or governance. Overall, the market reaction indicated a cautious but steady sentiment toward the company’s financial outlook.

Here is how related stocks have performed in the past 24 hours:

  • Sai Microelectronics (300456.SZ) traded flat 0 % and now trades at CNY 26.48. Current market capitalisation for Sai Microelectronics is CNY 20.5 bn. Sai Microelectronics has a current price to earnings ratio of 4.93.

  • Ugreen (301606.SZ) traded flat 0 % and now trades at CNY 46.5. Current market capitalisation for Ugreen is CNY 20.4 bn. Ugreen Group Ltd, a Chinese technology firm, has recently announced a strategic partnership with Tencent’s WorkBuddy to integrate AI‑powered agent capabilities into its NAS storage products. The collaboration aims to combine WorkBuddy’s task‑execution features with Ugreen’s 24‑hour online, locally stored, multi‑backup, and encrypted NAS solutions, enhancing the company’s open‑application ecosystem. Ugreen highlighted the growing demand for intelligent local data management driven by edge AI acceleration, and noted that its AI‑enhanced NAS offerings incorporate a proprietary operating system and an integrated assistant for natural‑language search, file organization, and knowledge‑base functionalities. The company’s focus on charging, smart office, entertainment, and storage products positions its NAS line as a key growth driver. The partnership is still under development, with details and launch timing to be disclosed in future official releases.

  • Keymed Biosciences (2162.HK) traded down -0.8 % and now trades at HKD 69.35. Keymed Biosciences has a market capitalisation of HKD 23.9 bn. Keymed Biosciences has a current price to earnings ratio of 24.25. Keymed Biopharma (02162.HK) experienced a significant decline in trading on the Hong Kong market, falling more than 14 percent during the day and again over 15 percent by midday. The drop was accompanied by notable short‑selling activity, with several hundred million dollars of shares sold short. Analysts at HSBC Global Investment Research noted that the recent US COINS Act proposals, while targeting primary‑market equity and acquisition deals, are unlikely to affect the company’s ongoing business‑development or co‑development plans. The brokerage maintained a buy rating for Keymed Biopharma, citing that the potential regulatory constraints are limited to certain types of transactions and that the company’s cash reserves and recurring business model remain solid. The market movement suggests that investors are weighing the impact of the new US restrictions while still viewing the firm’s longer‑term prospects positively.

  • Meihua (600873.SS) traded flat 0 % and now trades at CNY 7.26. Meihua has a market capitalisation of CNY 20.5 bn. Meihua has a current price to earnings ratio of 9.46.

  • Calb -H (3931.HK) traded down -0.37 % and now trades at HKD 13.22. Current market capitalisation for Calb -H is HKD 23.9 bn.

About Shanghai Haoyuan Chemexpre

Shanghai Haoyuan Chemexpress Co Ltd. is a Chinese company that is listed on the Shanghai Stock Exchange.